Read this topic

Imagine a patient whose family says something odd: some days she can hold a full conversation and remember visitors' names, and other days she is so confused she doesn't recognise her own kitchen. Ordinary dementias aren't supposed to work like that: they are supposed to get steadily worse, week by week, not swing wildly between good and bad within the same day. That single observation, wild swings rather than a steady slope, is the reason doctors carved dementia with Lewy bodies (often shortened to DLB; Lewy body dementia is simply an older name for the same condition) out as its own diagnosis rather than lumping it in with ordinary Alzheimer's disease. Getting the label right isn't just an academic exercise: the single most dangerous mistake in this condition is treating it like any other confused, hallucinating patient and reaching for a standard antipsychotic medicine, a mistake that can be lethal. So before any list of symptoms, hold onto one idea: DLB exists as a category because it behaves differently day to day and reacts differently to a common drug, and both differences change what a doctor should do next.

Strip away the jargon and DLB is a form of dementia (a progressive loss of memory and thinking ability caused by ongoing brain-cell damage) caused by tiny clumps of a misfolded protein building up inside nerve cells throughout the brain. A protein is misfolded when it twists into the wrong three-dimensional shape and clumps together instead of doing its normal job; picture a piece of paper meant to fold into a neat crane instead getting crumpled into a useless ball that jams up the machinery around it. These clumps, called Lewy bodies, build up inside brain cells that control alertness, vision-processing and movement, and the resulting damage produces a fairly recognisable three-part pattern: confusion that comes and goes, seeing things that are not there, and stiff, slow, tremor-prone movement similar to Parkinson's disease.

The single fact worth remembering above all others: people with DLB have severe, sometimes fatal, sensitivity to antipsychotic medicines, the drugs normally used to calm hallucinations or agitation. Antipsychotics work partly by blocking dopamine (a brain chemical messenger involved in both mood and movement) receptors. In most people that is a manageable side effect. In DLB, because the brain's dopamine system is already damaged by Lewy bodies, blocking dopamine further can trigger a reaction called neuroleptic sensitivity: sudden severe muscle rigidity, drowsiness, swings in blood pressure and temperature, and in the worst cases, death. This is why every textbook and every exam flags this condition specifically: recognising DLB before choosing a drug for hallucinations is a genuine bedside safety decision, not a diagnostic footnote.

Zoom into the misfolded protein itself: in DLB it is called alpha-synuclein (a protein normally found at the tips of nerve cells, helping them send signals to each other). When alpha-synuclein misfolds, it clumps into deposits called Lewy bodies inside the nerve cell body itself, rather than piling up in the spaces between cells the way the amyloid plaques of Alzheimer's disease do. Because the clumps sit inside brain regions that manage arousal and attention, the connections between those cells short out unpredictably rather than failing steadily, and that unpredictable short-circuiting is the root cause of the fluctuating confusion. Because the clumps also spread into the visual-processing pathways at the back and side of the brain, the misfiring circuitry produces vivid false perceptions rather than plain confusion. Because the same protein clumps up in the brainstem circuits that normally produce smooth, well-oiled movement (the same circuits damaged in Parkinson's disease), the patient develops slowness, stiffness and tremor. One shared cause, three different brain regions affected, three different symptoms: that is the whole logic of the triad.

Three core features together define the condition: fluctuating cognition (the patient's alertness and clarity of thought genuinely varies from hour to hour or day to day, not just morning tiredness), recurrent well-formed visual hallucinations (vividly seeing detailed people, children or animals that are not present, usually without the patient being frightened by them), and spontaneous parkinsonism (slowness of movement, muscle stiffness and tremor appearing without any drug cause). A fourth clue often arrives years earlier than any of these: REM sleep behaviour disorder (acting out dreams physically, e.g. punching, shouting or falling out of bed, during the dream stage of sleep when muscles are normally paralysed).

Consider a concrete case. A 74-year-old retired teacher is brought in because his wife reports he sometimes seems entirely himself over breakfast, then by mid-afternoon cannot follow a simple instruction and insists there is a dog sitting quietly in the corner of the room, though they have never owned one. She also mentions that for the past six years he has thrashed around and shouted during his sleep, once accidentally striking her. On examination he has mild stiffness in both arms and a slight tremor. Every piece fits the DLB pattern: the fluctuation, the calm and detailed hallucination, the parkinsonism, and a REM sleep behaviour disorder history stretching back long before any memory trouble began.

Alzheimer's disease is the closest look-alike, but its earliest and most prominent feature is memory loss (amnesia) that worsens in a fairly steady line, without the marked day-to-day fluctuation, and hallucinations, if they appear at all, arrive late and are far less vivid. Parkinson's disease dementia shares the same underlying alpha-synuclein pathology and can look almost identical, so doctors separate the two purely by timing: if the movement problems have been present for more than a year before any dementia develops, it is called Parkinson's disease dementia; if the dementia and the movement problems appear together, or the dementia comes first, it is called DLB. Creutzfeldt-Jakob disease (CJD, a rapidly progressive brain illness caused by misfolded prion proteins) can also cause rapid confusion, but it moves over weeks to months rather than years and is marked by myoclonus (sudden brief muscle jerks), which is not typical of DLB.

DLB is a clinical diagnosis (made from the history and examination, not a single blood test), formalised by an international agreement called the McKeith consensus criteria (a checklist doctors use so everyone means the same thing by DLB). A patient is diagnosed with probable DLB if they have dementia plus at least two of the four core features above (fluctuating cognition, visual hallucinations, spontaneous parkinsonism, REM sleep behaviour disorder), or just one core feature plus at least one indicative biomarker (a test result that strongly supports the diagnosis without being definitive alone). Three biomarkers count: a DaTscan (formally FP-CIT SPECT, a brain scan of the dopamine-carrying wiring) showing reduced uptake in the basal ganglia (deep movement-control structures); MIBG cardiac scintigraphy (a heart scan of the nerves supplying the heart) showing reduced signal, because DLB damages those nerves even outside the brain; or a sleep study (polysomnography) formally confirming REM sleep without the muscle paralysis that should normally accompany it. In practice, a typical exam vignette simply hands you the fluctuating-plus-hallucinations-plus-parkinsonism picture and expects you to recognise DLB without naming a scan: the criteria matter for knowing a formal diagnosis exists at all, not for memorising every biomarker.

UK practice follows NICE guidance (NG97, Dementia: assessment, management and support), which explicitly names DLB as a case where antipsychotics carry special risk. Cognitive symptoms and hallucinations are the first treatment target, and the first-line drugs are cholinesterase inhibitors (medicines that raise a brain chemical called acetylcholine by blocking the enzyme that breaks it down): rivastigmine has the strongest trial evidence in DLB, with donepezil also used. This is a genuinely high-yield exam fact: DLB is one of the few dementias where a cholinesterase inhibitor clearly helps hallucinations as well as cognition, unlike Alzheimer's disease where the same drug class mainly slows cognitive decline. Antipsychotics are avoided wherever possible for the neuroleptic-sensitivity reason above; if hallucinations are truly dangerous and unavoidable, only the lowest possible dose of a favourable-profile atypical such as quetiapine is used, under specialist supervision, never an older first-generation antipsychotic. Movement symptoms can be treated cautiously with levodopa (the same drug used in Parkinson's disease), started at the lowest effective dose and increased slowly, because it can worsen hallucinations and confusion even as it eases stiffness and slowness. REM sleep behaviour disorder is managed first with simple safety measures (padding the bedroom, removing sharp objects, a floor mattress) plus melatonin as first-line medication, with clonazepam as an alternative if melatonin is not enough. Alongside all of this, non-drug care matters just as much: educating carers about the fluctuating course so a bad day is not alarming, planning around fall risk, and building a calm, consistent routine.

The trap examiners set again and again is offering a confused, hallucinating elderly patient alongside a tempting antipsychotic answer option. The correct move is to recognise the fluctuating course, the vivid hallucinations, the parkinsonism, or the REM sleep behaviour disorder history as DLB, and avoid that option, favouring careful non-drug management or, if truly unavoidable, only the gentlest possible antipsychotic at a specialist-supervised low dose.

Dementia with Lewy bodies is a fluctuating dementia with vivid hallucinations and parkinsonism, caused by alpha-synuclein clumping inside neurons, and its single most important bedside fact is that antipsychotics can be dangerous.